Therefore it has been suggested that the modulators of the FAAH activity, as potential anti-IBS therapeutics, may provide finer tuning of the ECS function than the CB receptor ligands, also in terms of peripheral vs. central site-dependent site effects. This evidence concerns the gene FAAH and irritable bowel syndrome.